Oncimmune’s proprietary EarlyCDT® cancer detection tests are based on the presence in the blood of autoantibodies against specific tumour associated antigens that have the potential to detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types.

EarlyCDT-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer. When a tumour is present, it produces abnormal proteins (known as antigens). Cancer antigens are different to normal antigens so the body reacts to these antigens by producing autoantibodies. These autoantibodies, which can arise in the earliest stages of cancer and have been shown to be present at all stages, are produced in sufficient quantities to be measured in an individual’s blood using a simple blood test.

As a simple blood test, EarlyCDT-Lung can be used when a patient is at increased risk of lung cancer or for those patients who are unwilling or unable to commit to annual CT scanning.

Oncimmune’s EarlyCDT®–Lung test has undergone extensive scientific and clinical validation studies. More than 120,000 patient samples were run to validate its technical and clinical performance to 2012. Since then over 150,000 commercial tests have also been run.